These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 8996150

  • 1. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M.
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
    Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE.
    J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD.
    Cancer; 1999 Feb 15; 85(4):786-95. PubMed ID: 10091755
    [Abstract] [Full Text] [Related]

  • 4. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K, Man S, Mermershtain W, Cohen Y.
    J Chemother; 2002 Feb 15; 14(1):84-7. PubMed ID: 11892905
    [Abstract] [Full Text] [Related]

  • 5. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A.
    Cancer Chemother Pharmacol; 2003 Dec 15; 52(6):514-9. PubMed ID: 14504920
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Reina JJ, Aparicio J, Salvador J, Pica JM, Rueda A, Lorenzo A, de la Puente CG, Borrega P, Moreno-Nogueira JA.
    Cancer Chemother Pharmacol; 2003 Oct 15; 52(4):339-45. PubMed ID: 12851783
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P, Biglietto M, Casaretti R, De Lucia L, Avallone A, Maiorino L, Di Lullo L, De Cataldis G, Rivellini F, Comella G.
    Oncology; 2001 Oct 15; 60(2):127-33. PubMed ID: 11244327
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V.
    Br J Cancer; 2000 Aug 15; 83(4):431-7. PubMed ID: 10945486
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Luo HY, Li YH, Zhang L, Jiang WQ, Shi YX, Wang F, He YJ, Xu RH.
    Ai Zheng; 2007 Aug 15; 26(8):905-8. PubMed ID: 17697557
    [Abstract] [Full Text] [Related]

  • 15. Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
    Benavides M, García-Alfonso P, Cobo M, Muñoz-Martín A, Gil-Calle S, Carabantes F, Villar E, Graupera J, Balcells M, Pérez-Manga G.
    Med Oncol; 2004 Aug 15; 21(3):255-62. PubMed ID: 15456953
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G, Tucci A, Rinaldi A, Colarusso D, Pizza C, Reggiardo G, Manzione L.
    Oncology; 2004 Aug 15; 66(5):371-8. PubMed ID: 15331924
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 15; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 18. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
    Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P.
    J Clin Oncol; 1999 Sep 15; 17(9):2901-8. PubMed ID: 10561369
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.